Pharma sector to grow over 13%: Assocham

December 2006
Chemical Business;Dec2006, Vol. 20 Issue 12, p62
Trade Publication
The article reports on an expected increase of $9.48 billion of the Indian pharmaceutical industry through the help of global acquisitions and expansion within the country by 2010 according to the industry body Assocham. Only 1% of the global market and 8% in terms of volume are accounted for by the pharmaceutical market. Mergers and acquisitions and new product launches in the industry are the major trends anticipated in the future according to Assocham president Anil Agarwal.


Related Articles

  • Teva Back on Top. Houlton, Sarah // Pharmaceutical Executive;Sep2005, Vol. 25 Issue 9, p28 

    Reports on the acquisition of Ivax by pharmaceutical company Teva in the U.S. Annual sales of the drug manufacturer; Enhancement of the company's leadership in the global generics industry; Expansion of global generic and branded businesses with additional products; Extension of the client base.

  • COMPANY SPOTLIGHT - AstraZeneca PLC.  // PharmaWatch: Monthly Review;May2005, Vol. 4 Issue 5, p34 

    The article profiles pharmaceutical company AstraZeneca PLC in London, England. The company was formed through the merger of Swedish company Astra and British Zeneca making it the third largest pharmaceutical company in Europe and fourth in the U.S. Its products ranges from drugs used for...

  • Western Competition Forces Japanese Merger.  // Pharmaceutical Technology Europe;Jan2005, Vol. 17 Issue 1, p10 

    This article presents information related to Dainippon Pharmaceutical and Sumitomo Pharmaceutical that have merged, making it one of Japan's top ten pharmaceutical companies. This penetration of western pharmas is making the Japanese market more competitive and licensing opportunities for...

  • Issues Facing Biotech, Pharma Converge to Boost M&A Activity. Boogs, Jennifer // BioWorld International;3/11/2009, Vol. 14 Issue 10, p4 

    The article focuses on results of BioWorld Industry Snapshots that indicated a decrease in the number of merger and acquisition deals in the biotechnology industry. The report noted 150 deals closing in 2006, 125 in 2007 and 114 in 2008. However a confluence of factors such as drug industry's...

  • Reality not insanity. Miller, Jim // Pharmaceutical Technology Europe;Nov2009, Vol. 21 Issue 11, p16 

    The article discusses the initiatives taken by major global biopharmaceutical companies to deal with the issues of new product development. The author noted that drug companies have diversified their business portfolios through mergers, acquisitions and licensing deals. The author cited that...

  • Why Some Acquisitions Do Better Than Others: Product Capital as a Driver of Long-Term Stock Returns. Sorescu, Alina B; Chandy, Rajesh K; Prabhu, Jaideep C // Journal of Marketing Research (JMR);Feb2007, Vol. 44 Issue 1, p57 

    Corporate acquisitions are strategic actions that loom large in the minds of many senior managers. Despite decades of study, little systematic research exists on a central question: Why do the acquisitions of some firms perform better than those of others? The work that has examined this...

  • Big Pharma's Innovation Gap.  // njbiz;12/10/2007, Vol. 20 Issue 51, p12 

    The author highlights the slow pace of product introductions from the pharmaceutical industry in New Jersey. He says part of the problem is that drug-company mergers have centralized research & development (R&D) investment decisions in the hands of executives far from the actual research. Aside...

  • Leading Indian Pharma Companies Maintain Strong Growth. Ramesh, Deepti // Chemical Week;5/9/2007, Vol. 169 Issue 16, p49 

    The article reports on the strong earnings and sales growth posted by pharmaceutical companies in India during the first-quarter of 2007. Companies say that new product launches better results from international markets, and revenues from acquired companies have boosted growth. Ranbaxy...

  • Value chain is re-shaping the chip market, claims STMicro. Manners, David // Electronics Weekly;11/3/2004, Issue 2169, p4 

    The chip industry is consolidating around a few giants, which will each need 20 per cent world market share to maintain spending on developing product technology and building wafer fabs. Andrea Cuomo, vice president of advanced system technology at STMicroelectronics NV, outlined the industry's...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics